Mirum’s Brelovitug Meets Viral-Reduction Goal in Phase 3 Trial
The AZURE-4 study met its goal of reducing hepatitis delta virus levels as Mirum prepares for a potential FDA marketing application.
Makkler Newsroom · Nov 10, 06:56 PM · 1 min read
Mirum Pharmaceuticals, Inc. MIRM
NASDAQHealth TechnologyUnited States
$93.99+0.66 (+0.71%)
Market closed· · USD · Data may be delayed
- Day's range
- 91.3994.27
- 52-week range
- 63.23130.00
Financial health
– / 5
Analyst view · 15 firms
Buy15 buy · 0 hold · 0 sell
Avg. target $155.71 (+65.7%)
Prices may be delayed and are for informational purposes only - not investment advice.